A Randomized, Open Label Study to Compare the Safety and Efficacy of a Long Term Maintenance With TRIZIVIR After a Switch From a Boosted PI or a NNRTI as First Line Therapy for 96 Weeks.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Lamivudine/zidovudine/abacavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 26 Feb 2008 Status changed from recruiting to completed.
- 28 May 2007 New trial record.